The effectiveness use of the combined inhalation glucocorticosteroids in the therapy of bronchial asthma

10.12737/5482 ◽  
2014 ◽  
Vol 8 (1) ◽  
pp. 1-4
Author(s):  
Лепухова ◽  
O. Lepukhova
Keyword(s):  
Positive Result ◽  
Bronchial Asthma ◽  
Clinical Efficacy ◽  
Active Ingredient ◽  
Inflammatory Activity ◽  
Mixed Form ◽  
Inhalation Device ◽  
Acute Infections ◽  
Aerosol Inhalation ◽  
Pregnancy And Lactation

The effectiveness and comfort of using combined inhalation glucococrticosteroids in the patients with uncontrolled bronchial asthma of medium degree and mixed form was studied. As the reaction of application of different combined inhalation glucococrticosteroids for treating bronchial asthma of the same degree can be different, it is necessary to select not only the substance but also the form of using the preparations. So, for choosing the most effective preparation it was carried out an experiment with 40 patients aged from 18 to 65 with uncontrolled bronchial asthma of medium degree. The authors have excluded patients with: hyper sensibility to preparation components, acute infections of airways, pregnancy and lactation, presence a serious accompanying illness form. In the process of observation 2 patients dropped out of the experiment for different reasons. As a result 38 patients took part in research. The patients were divided into 2 groups. These patients received combined inhalation glucocorticosteroids in equivalent doses taking into account anti-inflammatory activity of glucocorticosteroid active ingredient and features of the inhalation device. The first group of patients used Foster aerosol inhalation in the dose of 100 mcg+ 6 mcg/1 dose: container 120 doses. The second group of patients received Foradil Kombi on form of gelatinous capsules, size 3 mg+12 mcg/ 1 dose together with powder for inhalations and included with the device for inhalation. Clinical efficacy of the treatment was assessed after 4 months of treatment and the positive result was detected in the second group.

Clinical efficacy of Kasakartari Gutika in the management Kasa in Tamaka Shwasa w.s.r. to Bronchial Asthma

2019 ◽  
Vol 4 (03) ◽  
Author(s):  
Pallavi T. Pawar ◽  
P. D. Londhe ◽  
C. S. Majgaonkar
Keyword(s):  
Bronchial Asthma ◽  
Clinical Efficacy ◽  
Prominent Symptom ◽  
Effective Remedy ◽  
Trial Drug

Background: The disease Kasa and Tamaka Shwasa mentioned by Acharya Charaka separately, both the disease are originating from Pranavaha Srotas and can damage Pranavaha Srotas permanently. Especially in Tamaka Shwasa Vyadhi, Kasa is very common as a prominent symptom. In fact patient gets more detoriated after onset of Kasa Vega and fills better when it gets subside. Though Tamaka Shwasa Vyadhi is Pitta Samudbhava, Kapha and Vata are always predominant factors. The Strotorodha made by Styana Kapha provocate Vayu excessively and result into Kasa Vega as symptom. According to Ayurveda the contain of Kasakartari Gutika is act as Kasa-shwashar property and hence for present study Kasakartari Gutika was selected as trial drug for treating the patient of Kasa in Tamaka Shwasa. Aim: To study the efficacy of ‘Kasakartari Gutika’ in the management of Kasa in Tamaka Shwasa w.s.r. to Bronchial Asthma. Material and Methods: Total 30 paients of Kasa in Tamaka Shwasa from OPD and IPD unit of Dr. M. N. Agashe Hospital, Satara, were selected and treated with Kasakartari Gutika 1gm B.D. for the duration of 2 month. Result: Maximum 81.81% relief was observed in Kshudhamandya and 80.64% relief was observed in Ayasenshwasa and 77.5% relief was observed in Kasa. Conclusion: The compound formulation ‘Kasakartari Gutika’ was found as an effective remedy for Kasa in Tamaka Shwasa. The parameters like Kasa, Ayasenshwasa and Kshudhamandya shows that they are highly significant result

Effect of Aerosol Inhalation of Budesonide Suspension on Clinical Efficacy, Remission Time of Asthma and Disappearance Time of Rales in Children with Mycoplasma Pneumoniae Pneumonia

2021 ◽  
Vol 7 (5) ◽  
pp. 3057-3062
Author(s):  
TingTing Zheng ◽  
XiNi Liu ◽  
Xuechun Chen
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Clinical Efficacy ◽  
Oral Treatment ◽  
Control Group ◽  
Study Group ◽  
Aerosol Inhalation ◽  
Significant Difference ◽  
Disappearance Time ◽  
And Control ◽  
Mycoplasma Pneumoniae Pneumonia

To investigate the effect of aerosol inhalation of budesonide suspension on clinical efficacy, remission time of asthma and disappearance time of rales in children with mycoplasma pneumoniae pneumonia. Methods: 100 cases of mycoplasma pneumoniae pneumonia in our hospital from February 2019 to February 2021 were randomly divided into study group (n = 50) and control group (n = 50). The control group was given azithromycin intravenous drip followed by oral treatment, and the study group was given aerosol inhalation of budesonide suspension on the basis of the control group. Results: Compared with the control group, disappearance time of rales in the study group, remission time of cough, remission time of asthma and time of hospitalization in the study group were relatively short (P<0.05), and the efficacy in the study group was relatively high (P<0.05). There was no significant difference in the incidence of nausea, vomiting, abdominal pain, diarrhea and hoarseness between the two groups (P>0.05). The improvement of FVCS FEV1 and PEF and other indexes was relatively high in the study group by comparing with the control group (P<0.05). Conclusion: Aerosol inhalation of budesonide suspension in children with mycoplasma pneumoniae pneumonia can effectively enhance the therapeutic effect, promote the improvement of lung function, and reduce the disappearance time of rales and remission time of asthma, so it can be popularized.

Clinical Efficacy of Ayurvedic formulations, Kanakasava and Trivrit Churna, in the Management of Bronchial Asthma: A Prospective, Open-label, Multicentric Study

2020 ◽  
Vol 4 (1) ◽  
pp. 1-9
Author(s):  
Narayanam Srikanth ◽  
Shruti Khanduri ◽  
Sobaran Singh ◽  
Thugutla Maheswar ◽  
Rakesh Rana ◽  
...  
Keyword(s):  
Bronchial Asthma ◽  
Clinical Efficacy ◽  
Open Label ◽  
Multicentric Study

Clinical Efficacy of Treatment of Children with Bronchial Asthma, Population in Remote Areas in Terms of Regional Respiratory Centre as Sanatorium Type: Work Results for 10 Years

10.12737/7279 ◽  
2014 ◽  
Vol 21 (4) ◽  
pp. 102-108
Author(s):  
Ермакова ◽  
I. Ermakova
Keyword(s):  
Bronchial Asthma ◽  
Clinical Efficacy ◽  
Clinical Examination ◽  
Main Group ◽  
Remote Areas ◽  
Number Of Children ◽  
Children With Asthma ◽  
Respiratory Centre ◽  
Severe Degree ◽  
Efficacy Of Treatment

The purpose of this work is to improve the specialized medical care for children with bronchial asthma, people living in remote areas and villages. Materials and methods: The study involved 1,024 children with asthma (solid sample, 2003) which were observed in period of 2003 to 2013. There are 391 children-villagers as the main group; clinical examination was carried out by district pediatrician and 633 children as regional city residents (the comparison group); clinical examination was carried out by district pediatrician together with pulmonologist or allergist. The author used the methods of observation (solid documentary and selective, current, prospective) and the method of expert evaluations. Results: a significant discrepancy (p=0,03) in the evaluation by district pediatrician, practitioner or family doctor) of severity bronchial asthma and absence of bronchial asthma treatment in 28% of patients of the main group has been demonstrated in 2003. The discrepancy in the diagnosis of bronchial asthma of light degree and medium severe degree (p=0.03) were detected by a positively accepted method (examination of pulmonologist/allergist, clinical and instrumental examination, 2008). Clinical efficacy of treatment of children with bronchial asthma as residents in regional respiratory centre has been proven. For ten years the number of children with BA decreased by 25%, the number of bronchial asthma patients with moderate current (p=0.03) decreased and the number of patients with medium severe degree bronchial asthma (p=0.01) significantly increased. In 2013, the patients of the main group observations received adequate basic therapy bronchial asthma; number of children with asthma decreased in 2 times (p=0.03); the calls in the ambulance and the need for hospitalization decreased more than 2 times (p=0.03); the number of children with controlled bronchial asthma increased from 26 to 64% (p=0.05).

scholarly journals The clinical efficacy of prophylactic therapy of the bronchial asthma in children with an early and late onset of the disease

2013 ◽  
Vol 17 (1 (65)) ◽  
pp. 106-109
Author(s):  
S. I. Sazhyn
Keyword(s):  
Bronchial Asthma ◽  
Clinical Efficacy ◽  
Early Onset ◽  
Odds Ratio ◽  
Late Onset ◽  
School Age Children ◽  
Prophylactic Therapy ◽  
School Age ◽  
Asthma In Children ◽  
Basic Treatment

The results of the clinical efficacy of basic treatment of school-age children with bronchial asthma have been presented. It has been found that patients with an early-onset phenotype of asthma had a higher risk of not gaining control over the symptoms of the disease (odds ratio – 6,0) and exacerbations (odds ratio – 2,7) compared with children whose disease set in after six years.

Usefulness of QVARTMfor the Treatment of Bronchial Asthma—With and Without Use of an Inhalation Device

2006 ◽  
Vol 43 (8) ◽  
pp. 613-618 ◽  
Author(s):  
Yuji Tohda ◽  
Fumio Tsuji ◽  
Hirokazu Kubo ◽  
Ryuta Haraguchi ◽  
Takashi Iwanaga
Keyword(s):  
Bronchial Asthma ◽  
Inhalation Device

Clinical efficacy of Kapha Ketu Rasa on Tamaka Swasa

2016 ◽  
Vol 1 (3) ◽  
Author(s):  
Anuroopa HK ◽  
Shankar Gouda ◽  
Madhava Diggavi
Keyword(s):  
Clinical Study ◽  
Success Rate ◽  
Bronchial Asthma ◽  
Clinical Efficacy ◽  
Eosinophil Count ◽  
Clinical Effect ◽  
Clinical Success ◽  
Clinical Success Rate ◽  
Therapeutic Effects

Context: Compound drugs are scientifically formulated aiming to get the desired therapeutic effects through synergy. Kapha Ketu Rasa is one such compound drug which is a classical herbo mineral marine Khalvi Rasayana judicially containing Shankha Bhasma, Vatsanabha, Tankana and Pippali. Treating GERD along with the treatment of bronchial asthma will enhance the clinical success rate. At this juncture, it is worth to notice the pharmacology of Kapha Ketu Rasa in the same perspective. Aims: To study the clinical effect of Kapha Ketu Rasa on Tamaka Swasa (Bronchial asthma). Materials and Methods: 30 Patients of Tamaka Swasa irrespective of age, sex, religion etc., were randomly selected and treated with 125 mg of Kapha Ketu Rasa capsules twice a day with Ardraka Swarasa before meals for 21 days, then followed for 21 more days. Results: The clinical study showed statistically highly significant improvement in both subjective and objective parameters viz. Kasa (91%), Ghurghurata (83%) and Swasakruchrata (82%) including decrease in AEC, ESR, Differential eosinophil count and PEF was also statistically significantly improved. Conclusions: Kapha Ketu Rasa is an effective Vyadhi Pratyanika herbo mineral Shamana Rasayana in the management of Tamaka Swasa.

Sign in / Sign up

Export Citation Format

Share Document